MARKET

KDMN

KDMN

Kadmon Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.845
-0.005
-0.10%
After Hours: 4.890 +0.045 +0.93% 17:59 01/21 EST
OPEN
4.940
PREV CLOSE
4.850
HIGH
4.940
LOW
4.745
VOLUME
2.05M
TURNOVER
--
52 WEEK HIGH
5.50
52 WEEK LOW
2.300
MARKET CAP
830.98M
P/E (TTM)
-8.1772
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Oppenheimer Sticks to Its Buy Rating for Kadmon Holdings (KDMN)
In a report released yesterday, Mark Breidenbach from Oppenheimer maintained a Buy rating on Kadmon Holdings (KDMN), with a price target of $8.00. The
SmarterAnalyst · 19h ago
Mizuho Securities Believes Kadmon Holdings (KDMN) Won’t Stop Here
Mizuho Securities analyst Mara Goldstein reiterated a Buy rating on Kadmon Holdings (KDMN) today and set a price target of $13.00. The company's shares
SmarterAnalyst · 2d ago
Kadmon gains 5% after Point72 discloses 5.3% stake
Steve Cohen’s Point72 Asset Management reports a 5.3% stake in Kadmon Holdings (KDMN), representing ~9.05M shares.Shares up 5% premarket.
Seekingalpha · 6d ago
The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14)
Benzinga · 6d ago
Steven Cohen Boosts Kadmon Holdings Stake
GuruFocus News · 6d ago
Kadmon Holdings, Inc. (NASDAQ:KDMN) Analysts Just Slashed Next Year's Revenue Estimates By 22%
The analysts covering Kadmon Holdings, Inc. ( NASDAQ:KDMN ) delivered a dose of negativity to shareholders today, by...
Simply Wall St. · 01/14 04:37
Kadmon Holdings, Inc. (NASDAQ:KDMN) Shares Could Be 47% Below Their Intrinsic Value Estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Kadmon Holdings, Inc...
Simply Wall St. · 12/14/2020 07:05
Kadmon Announced 12 Month Data from Pivotal Trial of Belumosudil for cGVHD With ORRs of 73% and 77% with Belumosudil 200 mg QD and 200 mg BID, Respectively at ASH 2020
Kadmon Holdings, Inc. (NASDAQ: KDMN) today announced 12-month data from ROCKstar, its ongoing pivotal trial of belumosudil for the treatment of patients with chronic graft-versus-host disease (cGVHD), in an oral session at the 62nd American Society of Hematology (ASH) Annual Meeting.
Benzinga · 12/06/2020 23:29
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KDMN. Analyze the recent business situations of Kadmon Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KDMN stock price target is 12.83 with a high estimate of 25.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 183
Institutional Holdings: 167.83M
% Owned: 97.85%
Shares Outstanding: 171.51M
TypeInstitutionsShares
Increased
49
20.90M
New
37
-1.59M
Decreased
42
15.19M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.30%
Pharmaceuticals & Medical Research
-0.53%
Key Executives
Non-Executive Chairman/Independent Director
Tasos Konidaris
President/Chief Executive Officer/Director
Harlan Waksal
Chief Financial Officer/Executive Vice President
Steven Meehan
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Gregory Moss
Executive Vice President
John Ryan
Director
Nancy Miller-Rich
Independent Director
Eugene Bauer
Independent Director
David Cohen
Independent Director
Arthur Kirsch
Independent Director
Cynthia Schwalm
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KDMN
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company's other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company's portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson's disease.
More

Webull offers kinds of Kadmon Holdings Inc stock information, including NASDAQ:KDMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KDMN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KDMN stock methods without spending real money on the virtual paper trading platform.